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Abstract Some novel triazolo[1,5-a]pyridine (4–6), thiazolo[3,2-a]pyridine (7),
thiazolo[3,2-a]pyrimidines (9, 11), oxoimidazo[1,2-a]pyrimidine (10), and pyrimi-
do[2,1-b]quinazoline (12) have been synthesized. The structures of target com-
pounds were confirmed by elemental analyses and spectral data. The antimicrobial
activity of some of the target synthesized compounds were tested against various
microorganisms such as Salmonella typhimurium, Pseudomonas aeruginos and
Staphylococcus aureus (bacteria), Aspergillus flavus (fungus), and Candida albicans
(yeast fungus) by the disc diffusion method. In general, the novel synthesized
compounds showed a good antimicrobial activity against these microorganisms.
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Introduction
The treatment of bacterial infections still remains an important and challenging
therapeutic problem because of factors that include emerging infectious diseases
and the increasing number of multi-drug-resistant microbial pathogens. In spite of
the large number of antibiotics and chemotherapeutics available for medical use, the
emergence of old and new antibiotic-resistant bacterial strains in recent decades
constitutes a substantial need for new classes of antibacterial agents [1]. Condensed
heterocyclic systems containing triazolo[1,5-a]pyridine are characterized by
significant pharmacological activity. These types of compounds exhibit antitumor,
antioxidant, analgesic, anti-inflammatory, antibacterial, antifungal activity, etc. [2–
7]. In addition to the previously mentioned properties, thiazolo[3,2-a]pyridines, also
containing two fused heterocyclic moieties in one molecule, are found in a broad
range of biologically active compounds and have many important bioactivities such
as inhibitors of beta-amyloid production [8], CDK2-cyclin-A [9], and a-glucosidase
[10], potential uterus stimulants [11, 12], and antibacterial and antifungal activities
[13], and are found to exhibit a broad spectrum of potent anticancer activity and are
useful for chemotherapy of various cancers, such as leukemia, lung cancer, and
melanoma [14]. On the other hand, certain pyrimidine derivatives are also known to
exhibit diverse pharmacological properties such as effective bactericides and
fungicides [15], as antimalarial [16], antioxidant [17, 18], and antihypertensive
agents, as adrenergic and neuropeptide antagonists [19] and having anti-HIV
activities [20, 21]. Along with the varied biological activities of pyrimidine, other
heterocycles fused with pyrimidines play an essential role in several biological
processes and have a considerable chemical and pharmacological importance
[22, 23]. In the view of these facts and as part of our efforts to discover potentially
active new agents, we have synthesized some new triazolo[1,5-a]pyridine,
thiazolo[3,2-a]pyridine, and dihydropyrimidinecarbonitrile, and their fused deriv-
atives. The novel derivatives were characterized by spectral data and elemental
analysis and tested for their antimicrobial activities.
Experimental
All melting points were uncorrected and were taken on a Boetius melting point
microscope. The infrared (IR) spectra were recorded on a Bruker-Vector 22,
Germany, using KBr discs at the microanalytical center, Cairo University. 1HNMR
spectra were performed on a Varian Gemini 300 MHz spectrometer and JEOL EX-
270 MHz at the Central Services Laboratory, National Research Centre, Cairo,
Egypt, using tetramethylsilane (TMS) as internal standard. All chemical shifts are
quoted in d values using parts per million scale (ppm) downfield from TMS. Mass
Spectra were recorded on a Hewlett-Packard 5988 A (1,000 Hz) instrument and
Shimadzu GCMS-QP-1000EX mass spectrometer at 70 eV at Cairo University.
Elemental analysis were performed by the Microanalytical unit at Cairo University
and the results were within ±0.4 of the theoretical values. All reactions were
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monitored by TLC using precoated aluminum sheet silica gel Merck 60F254 plates,
and detection of the components was made by short and long UV light.
1,6-Diamino-2-oxo-4-(5-methylfuran-2-yl)-1,2-dihydropyridine-3,5-
dicarbonitrile (3)
A mixture of freshly prepared cyanohydrazide (0.02 mol) and 2-((5-methylfuran-2-
yl)methylene)malononitrile (1) (0.01 mol) in absolute ethanol (25 mL) containing a
catalytic amount of piperidine was allowed to stir for 5 h at room temperature. The
resulting precipitate was filtered off and washed several times with ethanol and
crystallized from methanol to give 3 in 90 % yield; m.p. 290–292 C; IR (KBr,
cm-1) mmax: 3,381, 3,260 (2 NH2), 2,205 (CN), 1,638 (CO);
1HNMR (DMSO-d6) d:
2.38 (s, 3H, CH3), 5.61 (s, 2H, NH2), 6.45 (d, 1H, CH), 7.27 (d, 1H, CH), 8.31 (s,
2H, NH2); MS: m/z 255 (M
?) consistent with the molecular formula (C12H19N5O2).
2-Aryl-3,5-dihydro-7-(5-methylfuran-2-yl)-5-oxo-[1,2,4]triazolo[1,5-
a]pyridine-6,8-dicarbonitrile (4a–e)
A mixture of equimolar amounts of 3 and the appropriate aromatic or heterocyclic
aldehydes, namely, 4-bromobenzaldehyde, p-tolualdehyde, 3-indol aldehyde,
3-methoxybenzaldehyde and D-galactose, in ethanol was allowed to reflux for
8 h. The resulting precipitate was filtered off, washed several times with ethanol,
and crystallized from glacial acetic acid.
2-(4-Bromophenyl)-3,5-dihydro-7-(5-methylfuran-2-yl)-5-oxo-[1,2,4]triazolo[1,5-
a]pyridine-6,8-dicarbonitrile (4a)
Yield 78 %; m.p. 240–241 C; IR (KBr, cm-1) mmax: 3,432 (NH), 2,210 (CN);
1HNMR (DMSO-d6) d: 2.38 (s, 3H, CH3), 2.55 (s, 1H, NH), 6.38 (d, 1H, CH), 7.12




Yield 78 %; m.p. 230–232 C; IR (KBr, cm-1) mmax: 3,417 (NH), 2,210 (CN);
1HNMR (DMSO-d6) d: 2.38 (s, 3H, CH3), 2.56 (s, 3H, CH3), 6.38 (d, 1H, CH), 7.24
(d, 1H, CH), 7.37, 8.06 (2 dd, 4H, ArH), 8.30 (s, 1H, NH); MS: m/z 358 (M?2)
consistent with the molecular formula (C20H13N5O2).
2-(1H-Indol-3-yl)-3,5-dihydro-7-(5-methylfuran-2-yl)-5-oxo-[1,2,4]triazolo[1,5-
a]pyridine-6,8-dicarbonitrile (4c)
Yield 80 %; m.p. 263–265 C; IR (KBr, cm-1) mmax: 3,290, 3,205 (2 NH), 2,212
(CN), 1,621 (CO); 1HNMR (DMSO-d6) d: 2.42 (s, 3H, CH3), 6.48 (d, 1H, CH), 7.27
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(d, 1H, CH), 7.52, 8.15 (2 m, 4H, ArH), 8.79 (s, 1H, NH), 12.10 (s, 1H, NH); MS:
m/z 316 (M-64) consistent with the molecular formula (C21H12BrN6O2).
2-(3-Methoxyphenyl)-3,5-dihydro-7-(5-methylfuran-2-yl)-5-oxo-[1,2,4]triazolo[1,5-
a]pyridine-6,8-dicarbonitrile (4d)
Yield 80 %; m.p. 213–215 C; 1HNMR (DMSO-d6) d: 2.40 (s, 3H, CH3), 3.84 (s,




Yield 70 %; m.p. 240–241 C; IR (KBr, cm-1) mmax: 3,386 (OH), 3,279 (NH), 2,208
(CN), 1,635 (CO); 1HNMR (DMSO-d6) d: 2.38 (s, 3H, CH3), 2.86–3.31 (m, 2H, 60-
H, 600-H), 3.52 (m, 2H, 50-H, 40-H), 3.56 (t, 1H, 60-OH), 4.21–4.73 (m, 6H, 50-OH,




A mixture of equimolar amounts of 3 and ethylacetoacetate was refluxed for 3 h in
ethanol (25 mL). The precipitate formed was filtered off, washed several times with
ethanol, and crystallized from aqueous DMF to give compound 5 in 86 % yield;
m.p. 225–227 C; 1HNMR (DMSO-d6) d: 2.37 (s, 3H, CH3), 2.52 (s, 3H, CH3), 4.26
(s, 2H, CH2), 6.37 (s, 1H, CH), 7.10 (d, 1H, CH).
3,5-Dihydro-2-methyl-7-(5-methylfuran-2-yl)-5-oxo-[1,2,4]triazolo[1,5-
a]pyridine-6,8-dicarbonitrile (6)
A solution of (3) (0.002 mol) in freshly distilled acetic anhydride and acetic acid
(1:1) was reflux for 10 h. The precipitate formed on cooling to room temperature
was filtered off and crystallized from DMF to give compound (6) in 86 % yield;
m.p. 270–273 C; IR (KBr, cm-1) mmax: 3483 (NH), 2,214 (CN), 1,676 (CO);
1HNMR (DMSO-d6) d: 2.39 (s, 3H, CH3), 2.45 (s, 3H, CH3), 6.37 (s, 1H, CH), 7.24
(d, 1H, CH),7.94 (s, 1H, NH).
(2Z)-5-Amino-3,7-dihydro-7-(5-methylfuran-2-yl)-2-((5-methylfuran-2-
yl)methylene)-3-oxo-2H-thiazolo[3,2-a]pyridine-6,8-dicarbonitrile (7)
A solution of 1 (0.02 mol) and thioglycolic acid (0.01 mol) in ethanol (50 mL) and
a catalytic amount of piperidine was refluxed for 5 h. The solvent was concentrated
and the solid product was collected by filtration and recrystallized from ethanol to
give the title compound (7) in 91 % yield; m.p. 210–212 C; IR (KBr, cm-1) mmax:
3,396 (NH), 2,197 (CN), 1,700 (CO); 1HNMR (DMSO-d6) d: 2.38 (s, 3H, CH3),
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4.74 (s, 1H, CH), 6.05 (s, 1H, CH), 6.26 (d, 1H, CH), 6.46 (d, 1H, CH), 7.11 (d, 1H,




A mixture of ethyl cyanoacetate (0.1 mol), thiourea (0.1 mol) and 5-methylfurfural
(0.1 mol) in 50 mL sodium ethoxide (2.3 g, 0.1 mol) was stirred for 24 h at room
temperature and poured onto ice-water, and acidified with diluted HCl to give
precipitates, which were filtered off, dried, and crystallized from methanol to give
compound 8 in 76 % yield; m.p. 296–298 C; IR (KBr, cm-1) mmax: 3,424, 3,169 (2
NH), 2,216 (CN), 1,723 (CO); 1HNMR (DMSO-d6) d: 2.39 (s, 3H, CH3), 6.41 (d,
1H, CH), 7.40 (d, 1H, CH), 10.32 (s, 1H, NH, D2O exchangeable), 11.72 (s, 1H,
NH, D2O exchangeable);
13CNMR (DMSO): 15.17, 82.50, 117.43, 110.65, 1125.78,




A mixture of carbonitrile 8 (0.01 mol) and phenacyl bromide (0.01 mol) was
refluxed in ethanol for 5 h. After completion of the reaction, the precipitate formed
on hot was filtered, washed with ethanol, and dried to give compound 9 in yield of
69 %; m.p. 229–231 C; IR (KBr, cm-1) mmax: 2,206 (CN), 1,715 (CO); 1HNMR
(DMSO-d6) d: 2.36 (s, 3H, CH3), 5. 23 (s, 1H, CH), 6.28 (d, 1H, CH), 7.12–7.39 (m,
5H, ArH), 7.47 (d, 1H, CH); (C18H11N3O2S).
13CNMR (DMSO): 15.23, 98.36,
109.76, 110.22, 112.51, 116.80, 127.03, 129.12, 129.87, 135.45, 143.19, 135.93,




Equamolar mixture of thioxopyrimidine 8 (0.1 mol), and ethanolamine were heated
to reflux for 8 h. The reaction mixture was concentrated under reduced pressure, the
separated solid was collected by filtration and crystallized from glacial acetic acid to
afford compound 10 in 45 % yield, m.p. 251–253 C; IR (KBr, cm-1) mmax: 2,234
(CN), 1,714 (CO); 1HNMR (DMSO-d6) d: 2.38 (s, 3H, CH3), 3.02 (t, 2H, CH2), 3.76
(t, 2H, CH2), 6.43 (d, 1H, CH), 7.40 (d, 1H, CH), 10.32 (s, 1H, NH, D2O
exchangeable), 11.72 (s, 1H, NH, D2O exchangeable);
13CNMR (DMSO): 14.89,
40.09, 41.27, 98.84, 109.54, 112.33, 117.01, 153.41, 154.79, 159.50, 163.17,
170.85; MS: m/z 242 (M?) consistent with the molecular formula (C12H10N4O2).





A mixture of compound 6 (0.01 mol), chloroacetic acid (0.01 mol), required
aromatic aldehydes namely, 2,4,6-trimethyl benzaldehyde and 4-cyano benzalde-
hyde (0.01 mol) in a mixing solvent of acetic anhydride and acetic acid (10/20 mL)
in the presence of fused sodium acetate (0.5 g) was refluxed for 2 h. The solid
obtained was crystallized from proper solvent to give 11a, b, respectively.
(2Z)-2-(2,4,6-Trimethyl benzylidene)-3,5-dihydro-7-(5-methylfuran-2-yl)-3,5-dioxo-
2H-thiazolo[3,2-a]pyrimidine-6-carbonitrile (11a)
Yield 68 %; m.p. 243–246 C; IR (KBr, cm-1) mmax: 3,436, 3,173 (2NH), 2,219
(CN); 1HNMR (DMSO-d6) d: 2.24 (s, 3H, CH3), 2.37 (s, 9H, 3 CH3), 6.56 (d, 1H,
ArH), 7.29 (d, 1H, ArH), 7.94 (s, 1H, =CH); 13CNMR (DMSO): 15.04, 18.25,
24.13, 98.65, 109.22, 112.47, 116.37, 117.21, 127.80, 127.96, 135.06, 135.67,
135.82, 136.72, 143.58, 153.11, 154.61, 165.48, 165.34, 167.26, 171.18; MS: m/
z 386 (M?) consistent with the molecular formula (C20H10N4O3S).
(2Z)-2-(4-Cyanobenzylidene)-3,5-dihydro-7-(5-methylfuran-2-yl)-3,5-dioxo-2H-
thiazolo[3,2-a]pyrimidine-6-carbonitrile (11b)
Yield 68 %; m.p. 213–2125 C; IR (KBr, cm-1) mmax: 3,423, 3,119 (2NH), 2,209
(CN); 1HNMR (DMSO-d6) d: 2.24 (s, 3H, CH3), 6.67 (d, 2 H, ArH), 7.41 (d, 2 H,
ArH), 8.01 (s, 1H, =CH); 13CNMR (DMSO): 14.36, 98.16, 109.76, 111.43, 112.28,
116.95, 117.08, 117.54, 127.32, 134.15, 138.89, 147.35, 153.27, 154.88, 165.68,




A mixture of the thiouracil derivative 8 (0.01 mol) and anthranilic acid (0.01 mol)
were refluxed in sodium ethoxide solution (0.3 g sodium metal in 100 mL absolute
ethanol) for 12 h, cooled, and poured onto acidified ice-water. The obtained solid
was filtered off, washed with water, dried, and crystallized from DMF/water to give
compound 12, in yield of 57 %; mp. 268–269 C; IR (KBr, cm-1) mmax: 3217 (NH),
2220 (CN), 1719 (CO); 1HNMR (DMSO-d6) d: 2.34 (s, 3H, CH3), 6.28 (d, 1H, CH),
7.10–7.82 (m, 5H, CH ? ArH), 9.59 (s, 1H, NH, D2O exchangeable); MS: m/z 318
(M?) consistent with the molecular formula (C17H10N4O3).
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Results and discussion
1,6-Diamino-3,5-dicyano-4-(5-methylfuran-2-yl)-2-pyridone (3), [15] was prepared
in a good yield by reacting 2-((5-methylfuran-2-yl)methylene)malononitrile (1) with
cyanoacetohydrazide (2) in ethanol at room temperature in the presence of a catalytic
amount of piperidine. Formation of triazolo[1,5-a]pyridine derivatives 4a–e, 5 and 6
were prepared by reaction of the key intermediate 3 with appropriate aromatic and/or
sugar aldehydes, ethyl acetoacetate and acetic acid/acetic anhydride, respectively.
Also, reaction of the starting material 1 with thioglycolic acid in a molar ratio of 2:1 in
ethanol in the presence of a catalytic amount of piperidine gave (2Z)-5-amino-3,7-
dihydro-7-(5-methylfuran-2-yl)-2-((5-methylfuran-2-yl)methylene)-3-oxo-2H-
thiazolo[3,2-a]pyridine-6,8-di-carbonitrile (7) (Scheme 1).
On the other hand, the thioxopyrimidine heterocyclic core were constructed
according to Biginelli reaction by a cyclo-condensation of equivalent molar
quantities of 5-methylfurfural, thiourea, and ethyl cyanoacetate in sodium ethoxide
solution. After neutralization with acid, the desired 5-cyano-4-oxo-6-(5-methylfu-
ran-2-yl)-2-thioxo-1,2,3,4-tetrahydro-pyrimidine derivative (8) was obtained.
Treatment of 8 with phenacyl bromide and 2-ethanolamine in refluxing ethanol
afforded the fused rings bicyclic thiazolo[3,2-a]pyrimidines 9 and oxoimidazo[1,2-
a]pyrimidine 10, respectively. Syntheses of 2-arylmethylene derivatives 11a, b were
achieved in a single step by treating thioxopyrimidine derivative 8 with chloroacetic
acid and aromatic aldehydes in the presence of sodium acetate, acetic acid and
acetic anhydride. Compound 8 also reacted with anthranilic acid in sodium ethoxide
to yield 6,11-dihydro-2-(5-methylfuran-2-yl)-4,6-dioxo-4H-pyrimido[2,1-b]quinaz-






































































Scheme 1 Synthetic route for compounds 3–7
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Antimicrobial assay
Preparation of microbial suspensions
Seven compounds were tested for their antimicrobial activities against highly
pathogenic strains; one Gram-positive bacteria (Staphylococcus aureus), one Gram-
negative bacteria (Escherichia coli O157) isolated from minced meat, and two mycotic
strain (Candida albicans, Aspergillus flavus) isolated from mastitic milk. Agar disk
diffusion (qualitative method) and minimum inhibitory concentration (MIC) (quanti-
tative method) were used in this study. A suspension of bacterial and mycotic isolates
were freshly prepared by inoculating fresh stock culture from each strain into separate
broth tubes, each containing 7 mL of Muller Hinton Broth for bacterial strains and
Sabaroud Dextrose broth for mycotic strain. The inoculated tubes were incubated at 37
and 28 C for 24 h, respectively. Serial dilutions were carried out for each strain; the
dilution matching with 0.5 McFarland (about 1 9 108 cells/mL) was selected for
screening of antimicrobial activities. Ciprofloxacin 100 lg/mL and fluconazole 100 lg/
mL were used as reference drugs (Oxoid). DMSO was used as control negative.
Determination of antimicrobial activity by disc-diffusion method [24]
Muller Hinton and Sabaroud dextrose agar plates were prepared. Bacterial and














































a, R1=CH3 , R2=CH3 , R3=CH3





















Scheme 2 Synthetic route for compounds 8–12
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plates using sterile cotton swabs. For evaluation of antibacterial activities, Whatman
no. 1 filter paper disks were saturated with 50 lL of the compound dissolved in
DMSO (100 lg of the tested compound dissolved in 1 mL DMSO), others were
saturated with 50 lL ciprofloxacin (100 lg/mL), and others 50 lL DMSO as
control negative. The same method was used for evaluation of antimycotic activities
using fluconazole (100 lg/mL). Disks were dried and then placed onto inoculated
agar plates and left for 1 h at 25 C to allow a period of pre-incubation diffusion in
order to minimize the effects of variation in time between the applications of
different solutions. The plates were re-incubated at 37 and 28 C for 24 h for
bacterial and mycotic isolates, respectively. After incubation, plates were observed
for antimicrobial activities by determining the diameters of the zones of inhibition
for each of the samples. For an accurate analysis, tests were run in triplicate for each
strain to avoid any error.
Determination of minimum inhibitory concentration (MIC) [25]
Microtiter dilution plate quantitative method, i.e. the MIC was used for evaluation
of the antimicrobial activity of tested compounds. Determination of MIC of extract
against tested strains was achieved using 96-well sterile micro-plates. The first well
contain the concentrated form of the tested compound used in the agar disk diffusion
method (100 lg of the tested compound dissolved in 1 mL DMSO), then two-fold
serial dilutions was carried out for the tested compounds, reference drugs
(ciprofloxacin and fluconazole), and DMSO, Then, the wells were inoculated with
100 lL of tested isolates (0.5 McFarland, about 1 9 108 cells/mL) and incubated at
37–28 C for 24 h for bacterial and fungal strains, respectively. After incubation,
plates were examined visually for bacterial or fungal growth precipitation. The
experiment was repeated three times. The lowest concentration that showed
complete hindrance of growth was taken as MIC.
Table 1 Agar well diffusion method showing antimicrobial activities of the tested compounds compared
with reference drugs, results given in (mm)
Compounds Gram-negative bacteria Gram-positive bacteria Fungi
E. coli 0157 S. aureus C. albicans A. flavus
3 8 10 16 17
4a 9 12 18 10
4b Negative Negative 13 10
4e Negative Negative 19 16
6 7 13 17 12
7 Negative Negative 9 12
8 Negative Negative Negative Negative
DMSO Negative Negative Negative Negative
Fluconazole 100 lg/L ND ND 32 31
Ciprofloxacin 100 lg/L 42 39 ND ND
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Biological evaluation
All the newly synthesized compounds were screened for their in vitro antibacterial
activity against Gram-positive bacteria (S. aureus), and Gram-negative bacteria
(E. coli) using ciprofloxacin as the standard drug (100 lg/mL). They were also
evaluated for their in vitro antifungal activity against the mycotic isolates (C.
albicans, A. flavus) using fluconazole as a standard antifungal drug (100 lg/mL).
The agar well diffusion method [20] was used in this investigation for determination
of the preliminary antibacterial and antifungal activity and the results were recorded
for each tested compound as the average diameter (in mm) of inhibition zones (IZ)
of bacterial or fungal growth around the discs (Table 1). The minimum inhibitory
concentrations (MIC) were recorded for compounds that showed promising growth
inhibition using the two-fold serial dilution method [21]. The MIC (lg/mL) values
against the tested bacterial and fungal isolates were recorded in (Table 2). The agar
well diffusion method showed very weak activity of the compounds (3), (4a) and (6)
against bacterial isolates comparing with reference drugs, while other compounds
showing no hindrance of the tested compounds for the bacterial strains, The
antimycotic activity were more promising for the compounds (3) and (4e) with
mean zones of inhabitation equal to 16, 17, and 19 mm and 16 mm against C.
albicans and A. flavus, respectively, followed by compound (6) which showed a
zone of inhibition equaling 17 and 12 mm, then compounds (4a) and (4b) which
showed zones of hindrance against C. albicans equalling 18 and 13 mm compared
with reference drug (fluconozole) which give activity of 25 and 24 mm against C.
albicans and A. flavus, respectively. MIC was carried out against mycotic strains
only, and results against C. albicans showed that compound (4e) has the highest
hindrance capability at dilution 0.19 followed by compounds (3) and (6) with MIC
equal 1.56 against A. flavus. Compound (3) was the best with MIC 1.56 followed by
compound (4e) with MIC equal to 3.125 compared with fluconazole which gave
MIC equal to 0.097 for both tested strains.
Acknowledgments The authors would like to extend their sincere appreciation to the Deanship of
Scientific Research at King Saud University for its funding of this research through the Research Group
project no. RGP-VPP-320.
Table 2 The antimicrobial
activity of tested compounds
against bacterial and fungal











Fluconazole 100 mg/mL 0.097 0.097
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